

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Applicant : Balwani *et al.*  
Serial Number : Unassigned  
Filed : September 17, 2003  
Title : DECONGESTANT / ANTIHISTAMINIC /  
EXPECTORANT COMPOSITIONS  
Examiner : Unassigned  
Art Unit : Unassigned  
Attorney Docket No. : 452005.150

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

September 17, 2003

**INFORMATION DISCLOSURE STATEMENT**

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which may be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

  X   §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.  
No fee or statement is required.

- \_\_\_§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:
- (1) A Final Action or under 37 CFR §1.113; OR
  - (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

\_\_\_ The statement as specified in 37 CFR §1.97(e) set out below;  
OR

\_\_\_ The fee of \$180.00 under 37 CFR §1.17(p).

- \_\_\_§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND

\_\_\_ The fee of \$180.00 under 37 CFR §1.17(p).

- \_\_\_§1.97(e) The undersigned Attorney hereby states that:

\_\_\_ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

\_\_\_ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.


Serial No: Unassigned  
Filed: September 17, 2003

CERTIFICATE OF MAILING

Deposit Date: September 17, 2003

I hereby certify that this paper and the attachments hereto are being deposited today with the U.S. Postal Service with sufficient postage as First Class Mail to Addressee, under 37 CFR 1.8, on the date indicated above addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


  
Raymond E. Stauffer, Esq.

Date

9/17/03

#194922 v1 - no fee ids

Respectfully submitted,



Raymond E. Stauffer, Esq.  
Reg. No. 47,109  
CARELLA, BYRNE, BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
5 Becker Farm Road  
Roseland, NJ 07068  
Tel. No.: (973) 994-1700  
Fax No.: (973) 994-1744

Form PTO-1449  <u>INFORMATION DISCLOSURE STATEMENT</u>				Atty. Docket: 452005-150		Serial No.: Unassigned	
Applicant: Bulwani et al.							
Filing Date: September 17, 2003						Group: Unassigned	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Sub- Class	Filing Date
		6,462,094	10/8/02	Dang et al.	514	849	8/22/01
		6,417,206 B1	7/9/02	Leflein et al.	514	352	1/26/01
		6,306,904 B1	10/23/01	Gordziel	514	530	7/25/00
		6,287,597 B1	9/11/01	Gordziel	424	464	3/12/99
		6,037,358	3/14/00	Gordziel	514	357	3/24/99
		5,807,579	9/15/98	Vilkov et al.	424	469	11/14/96
		5,663,415	9/2/97	Chopdekar et al.	560	68	6/28/96
		5,599,846	2/4/97	Chopdekar et al.	514	653	6/28/96
		5,164,398	11/17/92	Sims et al.	514	282	4/1/91
		4,601,714	7/22/86	Burnhill	604	286	3/7/84
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Country	Class	Sub- Class	Translation
		64,007,786 (abstract)	8-31-93	JP	_____	_____	
		06287144	01-02-95	JP	_____	_____	
		39007786	05-18-64	JP	_____	_____	YES
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	Weiler et al., "Randomized, double blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan in the treatment of allergic rhinitis using an acute model," <i>Annals of Allergy</i> , vol. 64(1): 63-67						
	Goldberg et al., "Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders," <i>Clinical Medicine</i> , vol. 72(9): 1475-1479.						
	TRIPLE TANNATE, Drug Launches (doc. #: 0182701) 5/99						
	TUSSI-12, Drug Launches (doc. #: 0179128) 3/99						
	TUSSI-12, Drug Launches (doc. #: 0176901) 12/98						
Examiner:					Date Considered:		
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							



